Source: Eur Respir J 2010; 35: 692-694
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Allix-Beguec C, Fauville-Dufaux M, Stoffels K, Ommeslag D, Walravens K, Saegerman C, Supply P.. Importance of identifying Mycobacterium bovis as a causative agent of human tuberculosis. Eur Respir J 2010; 35: 692-694

Member's Comments

No comment yet.

Related content which might interest you: Identification of Mycobacterium tuberculosis (MTB)-infection in immunocompromised hosts Source: Annual Congress 2008 - Priorities for tuberculosis research in Europe: discussing the results of the Tuberculosis Network European Trials Group (TBNET) Year: 2008 Bedaquiline as a potential agent in the treatment of Mycobacterium abscessus infections Source: Eur Respir J, 49 (5) 1700083; 10.1183/13993003.00083-2017 Year: 2017 Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments Source: Eur Respir Rev, 31 (163) 210212; 10.1183/16000617.0212-2021 Year: 2022 Mycobacterium tuberculosis resistance Source: Eur Respir J 2002; 20: Suppl. 38, 360s Year: 2002 Bedaquiline as a potential agent in the treatment of M. intracellulare and M. avium infections Source: Eur Respir J , 49 (3) 1601969; DOI: 10.1183/13993003.01969-2016 Year: 2017 Clinical and laboratory features of Mycobacterium avium complex infection in comparison with infection, caused by Mycobacterium tuberculosis, in HIV-infected patients Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 On the nature of Mycobacterium tuberculosis-latent bacilli Source: Eur Respir J 2004; 24: 1044-1051 Year: 2004 Pulmonary diseases caused by non-tuberculous mycobacteria Source: Eur Respir Mon 2012; 58: 25-37 Year: 2012 Clinical relevance of Mycobacterium malmoense isolation in the Netherlands Source: Eur Respir J 2009; 34: 926-931 Year: 2009 Clinical relevance of differentiation between Mycobacterium avium and M. intracellulare in M. avium complex pulmonary disease in Croatia Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 Discriminating active from latent tuberculosis by Mycobacterium tuberculosis (MTB)-peptide specific immunoresponses Source: Annual Congress 2008 - Priorities for tuberculosis research in Europe: discussing the results of the Tuberculosis Network European Trials Group (TBNET) Year: 2008 Identification of nontuberculous mycobacteria using GenoType® Mycobacterium CM Source: Annual Congress 2010 - Nontuberculous mycobacterial infections and tuberculosis Year: 2010 Detection of Mycobacterium tuberculosis in children during complex antimycobacterial therapy Source: Annual Congress 2009 - Genetics of lung diseases Year: 2009 Invasive Mycobacterium avium intracellulare infection Source: Eur Respir J 2006; 28: Suppl. 50, 312s Year: 2006 Characterization of drug susceptibility of nontuberculous mycobacteria of M.chelonae and M.fortuitum complexes. Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria Year: 2018 The spectrum of drug susceptibility of slow-growing nontuberculous mycobacteria (MAC, M. kansasii, M. xenopi) Source: International Congress 2017 – Clinical challenges in chronic lung diseases Year: 2017 Serodiagnosis of Mycobacterium avium complex pulmonary disease in the USA Source: Eur Respir J 2013; 42: 454-460 Year: 2013 The role of genexpert in the diagnosis of mycobacterium tuberculosis Source: International Congress 2019 – Tuberculosis: diagnosis Year: 2019 Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis Source: Eur Respir J 2015; 46: 444-455 Year: 2015 Is delamanid a potential agent in the treatment of diseases caused by Mycobacterium avium-intracellulare? Source: Eur Respir J 2016; 48: 1803-1804 Year: 2016